Skip to main content

Alembic Pharma share price gains after tentative FDA nod for diabetes drug

 The firm has got the nod for empagliflozin and linagliptin tablets. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes.

Alembic Pharmaceuticals share price gained 3 percent intraday on August 27 after the pharma company received a tentative nod for the US drug regulator for empagliflozin and linagliptin tablets.

The company has received US Food & Drug Administration (USFDA) tentative approval for empagliflozin and linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg. Alembic now has a total of 130 ANDA approvals (113 final approvals and 17 tentative approvals) from the FDA, the company said in an exchange filing.

Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. However, the effectiveness of empagliflozin and linagliptin tablets in reducing the risk of cardiovascular death in adults with type 2 diabetes mellitus and cardiovascular disease has not been established, the company said.

Empagliflozin and linagliptin tablets (10 mg/5 mg and 25 mg/5 mg) had an estimated market size of $244 million for twelve months ending June 2020, the company said, citing IQVIA data.



The stock, which has gained 57 percent in the past six months, was trading at Rs 1,022.40, up Rs 31.60, or 3.19 percent. It has touched an intraday high of Rs 1,024.45 and an intraday low of Rs 990.80.

The drug company on August 25 said its joint venture partner Aleor Dermaceuticals received final approval from the US regulator for Desonide lotion used to treat a variety of skin conditions. The approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to the reference listed drug product DesOwen Lotion, 0.05 percent, of Galderma Laboratories LP.



According to Moneycontrol SWOT Analysis powered by Trendlyne, the company has zero promoter pledge with book value per share improving for the past two years

Moneycontrol technical rating is bullish with moving averages and technical indicators being bullish.

Disclaimer: The views and investment tips expressed by experts on moneycontrol.com are their own and not those of the website or its management. Moneycontrol./SD Solutions com advises users to check with certified experts before taking any investment decisions.

Labels:

Comments

Post a Comment

Popular posts from this blog

Reliance Jio Q3 results: Profit grows to Rs 3,489 crore; ARPU rises to Rs 151

  The average revenue per user (ARPU) during the quarter came at Rs 151 per subscriber per month as against Rs 145 per subscriber per month in the September quarter. Reliance Jio, the telecommunications arm of Jio Platforms, on January 22 posted a net profit of Rs 3,489 crore for the quarter ended December 31, 2020. The profit was higher than the street expectations as analysts in a CNBC-TV18 poll had estimated the number at Rs 3,200 crore. Jio's net profit grew 15.5 percent QoQ as in the September quarter of FY21, its profit was Rs 3,020 crore. The average revenue per user (ARPU) during the quarter came at Rs 151 per subscriber per month as against Rs 145 per subscriber per month in the September quarter. A CNBC-TV18 poll had estimated ARPU at Rs 148.2. Revenue, including access revenues for the quarter, was Rs 22,858 crore ($3.1 billion), up 5.3 percent QoQ. A CNBC-TV18 poll had estimated revenue to the tune of Rs 18,165 crore. EBITDA for the quarter stood at Rs 8,483 crore ...
Post a Comment
Read more

Futures Trade | A bullish breakout of a flag pattern in HDFC

HDFC is moving in an uptrend with a minor corrective decline. The range is classified as a flag and a breakout of falling minor trendline confirms a possible upside. HDFC is moving in an uptrend with a minor corrective decline from Nov 20 highs. The decline is on lower, contracting volumes and suggests a correction within an ongoing trend. The range-bound action can also be classified as a flag as it is on coming off a sharp rally. A breakout of falling minor trendline confirms a possible upside. Buy around Rs 2300-2310. Keep a stop below Rs 2250 and hold for a target of Rs 2400 and above that to Rs 2450.
Post a Comment
Read more

Ashoka Buildcon share price up 4% on bagging 2 NHAI projects

The share touched its 52-week high Rs 127.90 and 52-week low Rs 37.00 on 23 September, 2019 and 03 April, 2020, respectively. Ashoka Buildcon share price added over 4 percent in early trade on September 8 after the company emerged as the lowest bidder (L-1) for the two NHAI projects. The aggregate quoted value of the projects is Rs 1,390 crore. The company had submitted bids to National Highway Authority of India (NHAI) for the project of four laning of Arra h to Pararia section of NH-319(Old NH-30) in the State of Bihar under Bharatmala pariyojana Phase -1 on EPC Mode (Package-I) and Four laning of Pararia to Mohania section of NH-319(Old NH-30) in Bihar under Bharatmala Pariyojana Phase-I on EPC Mode (Package II). At 09:23 hrs Ashoka Buildcon was quoting at Rs 70.60, up Rs 2.40, or 3.52 percent on the BSE. The share touched its 52-week high Rs 127.90 and 52-week low Rs 37.00 on 23 September, 2019 and 03 April, 2020, respectively. Currently, it is trading 44.8 percen...
Post a Comment
Read more